Worldwide physician education and training in pulmonary hypertension: Pulmonary vascular disease: The global perspective

Chest

Volumn 137, Issue 6 SUPPL., 2010, Pages 85S-94S

  Elliott, C Gregory ^a,b   Barst, Robyn J ^c   Seeger, Werner ^d   Porres Aguilar, Mateo ^b   Brown, Lynette M ^a,b   Zamanian, Roham T ^e   Rubin, Lewis J ^f  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

CLINICAL COMPETENCE; CONTINUING EDUCATION; EDUCATION PROGRAM; EVIDENCE BASED PRACTICE; MEDICAL EDUCATION; MEDICAL SPECIALIST; PHYSICIAN; POSTGRADUATE EDUCATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SURGICAL TECHNIQUE;

EID: 77953295281     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-2816     Document Type: Review

References (80)

1. Alarcón DG. Worldwide chest medicine. New trends in medical education imposed by achievements in diagnosis and therapy of respiratory and cardiovascular diseases. Dis Chest. 1967;51(2):213-215.
2. Mocumbi P. Pulmonary vascular diseases: a truly neglected group of diseases. Pulmonary Vascular Research Institute Review. 2009;1(1):2.
3. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med. 2009;179(8):650-656.
4. Machado RF. Pulmonary hypertension in sickle cell disease. Pulmonary Vascular Research Institute Review. 2009;1(1):6-12.
5. Harikrishnan S. Pulmonary hypertension in rheumatic heart disease. Pulmonary Vascular Research Institute Review. 2009;1(1):13-19.
6. Menon S. Pulmonary hypertension in the South East Asia region: an analysis of indexed publication profile. Pulmonary Vascular Research Institute Review. 2009;1(3):167-172.
7. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol(prostacyclin). Lancet. 1984;1(8385):1046-1047. (Pubitemid 14148935)
8. Barst RJ, Rubin LJ, Long WA, et al;The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
9. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-434.
10. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327(2):76-81.
11. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903.
12. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982;306(10):557-564.
13. Moser KM, Daily PO, Peterson K, et al. Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension. Immediate and long-term results in 42 patients. Ann Intern Med. 1987;107(4):560-565.
14. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. Nov 2003;76(5):1457-1462.
15. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157.
16. Butrous G, Morrell N. Pulmonary hypertension associated with schistosomiasis taskforce. Pulmonary Vascular Research Institute Review. 2009;1(1):53-58.
17. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-1030.
18. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007;30(1):104-109.
19. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1-22, vii.
20. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S43-S54.
21. Kumar U, Ramteke R, Yadav R, Ramam M, Handa R, Kumar A. Prevalence and predictors of pulmonary artery hyperten sion in systemic sclerosis. J Assoc Physicians India. 2008;56:413-417.
22. Phung S, Strange G, Chung LP, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J. 2009;39(10):682-691.
23. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension:state of the art. Ann Hepatol. 2008;7(4):321-330.
24. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178(6):637-643.
25. Hua R, Sun YW, Wu ZY, et al. Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. Hepatobiliary Pancreat Dis Int. 2009;8(2):157-161.
26. Lapa M, Dias B, Jardim C, et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation. 2009; 119(11):1518-1523.
27. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-487.
28. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med. 2008;177(6):574-579.
29. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9):886-895.
30. Murphy D, Girgis RE. HIV-associated pulmonary arterial hypertension: a clinical problem that is here to stay? Int J Clin Pract. 2009;63(s 161):19-21.
31. Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease:an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120(2):198-204.
32. Burger CD. Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. COPD. 2009;6(2):137-144.
33. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371-1385.
34. Pengo V, Lensing AW, Prins MH, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.
35. Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome. Drugs. 2008;68(8):1049-1066.
36. Idrees M, Ghofrani A, Hassoun P. PVRI Eastern Mediterranean region taskforce. Pulmonary Vascular Research Institute Review. 2009;1(1):62-63.
37. Haworth S, Kumar K. PVRI Indian subcontinent taskforce. Pulmonary Vascular Research Institute Review. 2009;1(1):63-65.
38. Wilkins M, Wang C. PVRI China taskforce. Pulmonary Vascular Research Institute Review. 2009;1(1):66.
39. UNAIDS. 2006 Report on the Global AIDS Epidemic. Geneva, Switzerland: Joint United Nations Program on HIV/AIDS;2006.
40. Engels D, Chitsulo L, Montresor A, Savioli L. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Tropica. 2002;82(2) 139-146. (Pubitemid 34518564)
41. World Health Organization. Monogenic diseases. http://www.who.int/ genomics/public/geneticdiseases/en/index2.html#SCA. Accessed May 2, 2009.
42. Serjeant GR. Sickle-cell disease. Lancet. 1997;350(9079):725-730.
43. Sani MU, Karaye KM, Borodo MM. Prevalence and pattern of rheumatic heart disease in the Nigerian savannah: an echocardiographic study. Cardiovasc J Afr. 2007;18(5):295-299. (Pubitemid 351412386)
44. Rheumatic fever and rheumatic heart disease. World Health Organ Tech Rep Ser. 2004;923 :1-122.
45. Richalet J-P, Rivera M, Maignan M, Pham I, Privat C, Leon-Velarde F. Pulmonary hypertension and Monge's disease. Pulmonary Vascular Research Institute Review. 2009;1(2): 114-119.
46. Monge CC, Whittembury J. Chronic mountain sickness. Johns Hopkins Med J. 1976;139(SUPPL):87-89.
47. Tan WC, Ng TP. COPD in Asia:where East meets West. Chest. 2008;133(2):517-527.
48. Badesch DB, Abman SH, Ahearn GS, et al;American College of Chest Physicians. Medical therapy for pulmonary arterial hypertension:ACCP evidence-based clinical practice guidelines. Chest. 2004;126(1 suppl):35S-62S.
49. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131(6):1917-1928.
50. McLaughlin VV, Archer SL, Badesch DB, et al; ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-2294.
51. Barst RJ, Seeger W. PVRI fellowship taskforce. Pulmonary Vascular Research Institute Review. 2009;1(1):67-68.
52. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S55-S66.
53. Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S78-S84.
54. Ghofrani HA, Barst RJ, Benza RL, et al. Future perspectives for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S108-S117.
55. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(1 suppl):S10-S19.
56. Hoeper MM, Barberà JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S85-S96.
57. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S67-S77.
58. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S32-S42.
59. McLaughlin VV, Badesch DB, Delcroix M, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S97-S107.
60. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S20-S31.
61. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 suppl):S3-S9.
62. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195-1203. (Pubitemid 44883856)
63. Galiè N, Olschewski H, Oudiz RJ, et al;Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies(ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy(ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019.
64. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-1482.
65. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858-1865. (Pubitemid 29181415)
66. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170(11):1212-1217.
67. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780-788.
68. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338(5):273-277. (Pubitemid 28065252)
69. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113(16):2011-2020.
70. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100.
71. Charap MH, Levin RI, Pearlman RE, Blaser MJ. Internal medicine residency training in the 21st century: aligning requirements with professional needs. Am J Med. 2005;118(9):1042-1046.
72. Buckley JD, Addrizzo-Harris DJ, Clay AS, et al. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine. Am J Respir Crit Care Med. 2009;180(4):290-295.
73. Petty TL, Briggs DD, Braddy DE. Educating tomorrow's chest physician. An international challenge. Chest. 1983;83(6):840-841.
74. McGaghie WC, Siddall VJ, Mazmanian PE, Myers J; American College of Chest Physicians Health and Science Policy Committee. Lessons for continuing medical education from simulation research in undergraduate and graduate medical education: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines. Chest. 2009;135(3 suppl):62S-68S.
75. Leach DC, Fletcher SW. Perspectives on continuing education in the health professions: improving health care through lifelong learning. Chest. 2008;134(6):1299-1303.
76. Galiè N, Hoeper MM, Humbert M, et al; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT). Eur Heart J. 2009;30(20):2493-2537.
77. Humbert M, McLaughlin VV. The 4th World Symposium on Pulmonary Hypertension. Introduction. J Am Coll Cardiol. 2009;54(1 suppl):S1-S2.
78. Pulmonary Artery Catheter Education Project. Pulmonary artery catheter education project. http://www.pacep.org/. Accessed February 10, 2010.
79. Pulmonary Hypertension Association. Pulmonary Hypertension Association. http://www.phassociation.org/. Accessed February 10, 2010.
80. Bukachi F, Pakenham-Walsh N. Information technology for health in developing countries. Chest. 2007;132(5):1624-1630.